ETFChannel.com
VRTX Description — Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. Co.'s marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta-thalassemia.

Company Name: 
Vertex Pharmaceuticals, Inc.
Website: 
www.vrtx.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding VRTX: 
88
Total Market Value Held by ETFs: 
$8,924,633,398
Total Market Capitalization: 
$70,523,000,000
% of Market Cap. Held by ETFs: 
12.65%
 ETF   VRTX Weight   VRTX Amount 
 VTI   0.22%   $2,064,106,605         
 VOO   0.26%   $1,502,680,157         
 SPY   0.26%   $773,651,603         
 IBB   7.49%   $745,682,860         
 VUG   0.44%   $572,114,850         
 IVV   0.26%   $550,043,570         
 USMV   1.38%   $476,636,898         
 XLV   1.80%   $439,016,160         
 IWF   0.45%   $264,711,770         
 VHT   1.51%   $199,982,702         
List of all 88 ETFs holding VRTX »
Quotes delayed 20 minutes

Strong Buy (3.52 out of 4)
66th percentile
(ranked higher than approx. 66% of all stocks covered)

Analysts Forecast:
VRTX Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding VRTX | Vertex Pharmaceuticals, Inc. | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.